For how we live.
Triglycerides are the lipid panel's fourth number, and most of what raises them is modifiable. Here is where the thresholds sit — and the point at which a very high level becomes a medical emergency.
In the Novartis-funded VICTORION-Challenge trial, twice-yearly inclisiran cut LDL 56.3% at day 150 against 15.4% for daily bempedoic acid — an open-label comparison of a surrogate marker, not outcomes.
CORE and CORE2 enrolled 1,061 patients with severe hypertriglyceridaemia. The pancreatitis rate ratio was 0.15, but the higher dose came with liver enzyme rises and low platelets.
The first phase 1 results for CTX310 show gene editing can switch off a lipid gene in the liver. The trial was designed to look for harm, not benefit, and one participant died suddenly.
Carriers of loss-of-function MC4R mutations had lower LDL and triglycerides than UK Biobank controls of similar adiposity, and lower cardiovascular risk. The brain sets body weight and lipids separately.